Skip to main contentAI and Advanced
/
CONCORDBIO · NSEMarket ticker unavailable · configure an authorised index feed
CO
NSE · Equity shares · Biotechnology & Drugs-28.80 · -1.96%
Concord Biotech CONCORDBIO
NSE:INR 1,441.2
BSE:INR 1,370
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for CONCORDBIO
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,470
Day rangeINR 1,428.1 — INR 1,484.2
52-week rangeINR 987 — INR 1,704
Volume1.06 L
Market cap14,332.42
P/E48.66
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,054.89
Net Income (INR Cr)260.91
Rev Growth (5 Year %)11.32
EPS Growth (5 Year %)2.12
P/E Ratio48.66
EPS25.17
Research path: Interpret Concord Biotech's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
CONCORDBIOConcord Biotech1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 2,234.73 | 2,034.25 | 1,700.71 |
| Accumulated Depreciation Total | -361.98 | -290.43 | -240.15 |
| Other Liabilities Total | 3.72 | 2.82 | 1.96 |
| Common Stock Total | 10.46 | 10.46 | 10.46 |
| Other Equity Total | 1.52 | Not available | Not available |
| Other Current Assets Total | 1.22 | 3.69 | 12.74 |
| Prepaid Expenses | 7.56 | 7.39 | 7.33 |
| Total Assets | 2,234.73 | 2,034.25 | 1,700.71 |
| Current Portof LT Debt/Capital Leases | 0.88 | 2.34 | 7.85 |
| Additional Paid-In Capital | 81.97 | 81.97 | 81.97 |
| Cash | 12.19 | 0.9 | 15.14 |
| Total Equity | 2,018.98 | 1,812.72 | 1,526.65 |
| Long Term Investments | 95.05 | 34.76 | 3.05 |
| Retained Earnings(Accumulated Deficit) | 1,925.03 | 1,720.28 | 1,434.21 |
| Total Common Shares Outstanding | 10.46 | 10.46 | 10.46 |
| Property/Plant/Equipment Total-Gross | 1,228.04 | 1,134.65 | 1,026.63 |
| Tangible Book Valueper Share Common Eq | 192.82 | 173.17 | 145.9 |
| Goodwill Net | 0.4 | Not available | Not available |
| Total Liabilities | 215.74 | 221.53 | 174.06 |
| Total Debt | 2.32 | 2.97 | 9.74 |
| Short Term Investments | 418.66 | 334.53 | 266.52 |
| Cashand Short Term Investments | 430.85 | 335.44 | 281.67 |
| Total Receivables Net | 479.02 | 547.48 | 378.89 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Deferred Income Tax | 45.36 | 34.02 | 28.06 |
| Accounts Receivable-Trade Net | 460.2 | 521.65 | 350.84 |
| Property/Plant/Equipment Total-Net | 866.06 | 844.22 | 786.48 |
| Minority Interest | -3.85 | Not available | Not available |
| Total Current Liabilities | 169.08 | 184.06 | 142.16 |
| Total Inventory | 331.47 | 241.24 | 215.61 |
| Accounts Payable | 101.91 | 113.04 | 94.44 |
| Other Currentliabilities Total | 66.29 | 68.68 | 39.77 |
| Total Long Term Debt | 1.43 | 0.63 | 1.89 |
| Intangibles Net | 1.42 | 1.12 | 0.32 |
| Other Long Term Assets Total | 7.86 | 7.91 | 2.16 |
| Note Receivable-Long Term | 13.83 | 11 | 12.47 |
| Total Current Assets | 1,250.11 | 1,135.24 | 896.23 |
| Capital Lease Obligations | 1.43 | 0.63 | 1.89 |
| Accrued Expenses | Not available | 0 | 0.1 |
| Long Term Debt | Not available | 0 | 0 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio18.73
Price to Sale Ratio13.59
Growth
Debt 5Yr CAGR %-51.83
Margins
Operating Margin 12m28
Operating Margin 5y Avg33.91
Net Profit Margin 12m24.62
Net Profit Margin 5y27.99
Yield
Dividend Yield %0.55
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk42.14
Analyst consensus
ConsensusBuy
Consensus score2.25
Analyst opinions4
Strong Sell count0
Sell count0
Hold count2
Buy count1
Strong Buy count1
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 44.08%
- FII
- 7.53%
- MF
- 4.40%
- Other
- 43.99%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Is It Worth Considering Concord Biotech Limited (NSE:CONCORDBIO) For Its Upcoming Dividend? - simplywall.stMarket news · 20 Jul 2026, 6:59 am
Is It Worth Considering Concord Biotech Limited (NSE:CONCORDBIO) For Its Upcoming Dividend? simplywall.st
CarTrade Tech, Concord Biotech, Apar Industries shares rise up to 8% today; here's why - MSNMarket news · 17 Jul 2026, 9:52 pm
CarTrade Tech, Concord Biotech, Apar Industries shares rise up to 8% today; here's why MSN
Price to book forward of Concord Biotech Ltd. – NSE:CONCORDBIO - TradingViewMarket news · 15 Jul 2026, 8:00 pm
Price to book forward of Concord Biotech Ltd. – NSE:CONCORDBIO TradingView
Concord Biotech - Positive Breakout: These 14 stocks cross above their 200 DMAs - The Economic TimesMarket news · 10 Jul 2026, 11:44 am
Concord Biotech - Positive Breakout: These 14 stocks cross above their 200 DMAs The Economic Times
Concord Biotech fixes record date for ₹7.55 dividend - scanx.tradeMarket news · 8 Jul 2026, 12:30 pm
Concord Biotech fixes record date for ₹7.55 dividend scanx.trade
Enterprise value to EBIT forward of Concord Biotech Ltd. – NSE:CONCORDBIO - TradingViewMarket news · 7 Jul 2026, 5:42 pm
Enterprise value to EBIT forward of Concord Biotech Ltd. – NSE:CONCORDBIO TradingView
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.7.5500 per share(755%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.10.7000 per share(1070%)Final Dividend
Rusaka Markets Community
Discussion and sentiment for Concord Biotech
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Concord Biotech Limited is an India-based research and development-driven biopharmaceutical company focused on manufacturing fermentation-based active pharmaceutical ingredients (APIs) and formulations. The Company is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its product portfolio encompasses both biopharmaceutical APIs and formulations across various therapeutic areas, including immunosuppressants, oncology, anti-infectives, nephrology, and critical care. Its API products include Immunosuppressant, Oncology Drugs, Anti-bacterial, and others. Its Immunosuppressant include Tacrolimus, Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, and Voclosporin. Its Oncology Drugs include Temsirolimus, Everolimus, Romidepsin, Mitomycin, Dactinomycin, Midostaurin, and Doxorubicin. Its Anti-bacterial include Mupirocin, Mupirocin Calcium, Teicoplanin, and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- CONCORDBIO
- BSE Code
- 543960
Questions
Stock FAQ
What is the symbol and ISIN of Concord Biotech?
Concord Biotech has the symbol CONCORDBIO and ISIN - INE338H01029.
What is the current price of Concord Biotech?
Concord Biotech is currently trading at INR 1,441.20.
What are the year high and year low of Concord Biotech?
Concord Biotech has a year high of INR 1,704.00 and a year low of INR 987.00.
What is the market capitalization of Concord Biotech?
Concord Biotech has a market capitalization of INR 14,332.42 crore.
What is the P/E ratio of Concord Biotech?
Concord Biotech has a P/E ratio of 48.66.
What is the dividend yield of Concord Biotech?
Concord Biotech has a dividend yield of 0.55%.
How is the financial performance of Concord Biotech based on revenue, net income, and EPS?
Concord Biotech has revenue of INR 1,054.89 crore, net income of INR 260.91 crore, and EPS of INR 26.54.
What is the book value of Concord Biotech?
Concord Biotech has a book value of NA.
What is the debt-to-equity ratio of Concord Biotech?
Concord Biotech has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Concord Biotech?
Concord Biotech has a price-to-book ratio of NA and a price-to-sales ratio of 13.59.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.